An experimental malaria vaccine GlaxoSmithKline PLC filed with regulators Thursday could help fight one of the world's biggest killers—but rival company Sanaria Inc. has a potentially more effective shot in the works.. If Europe's regulators give Glaxo's vaccine—called RTS,S—the green light, it could be in use as soon as 2015, paving the way for a mass vaccination program across sub-Saharan Africa.. That...
  